Petco Health reported flat revenue of $1.49 billion in Q2, with operational improvements mainly due to one-off tariff refunds rather than growth in its core business. The company's financial position remains strained, carrying $1.46 billion in long-term debt and a low interest coverage ratio of 1.5x, indicating ongoing risk. Management reaffirmed full-year 2026 guidance, factoring in tariff refunds, but Q3 adjusted EBITDA guidance of $100–$103 million is lower than Q2, which has dampened investor confidence. The analyst maintains a neutral outlook, awaiting clearer signs of sustained operational improvement before considering a positive rating change.
McCormick & Company received a Buy rating due to its margin expansion, operational efficiency, and a strong innovation pipeline targeting 2026. The company reported a 30.1% increase in adjusted operating income in Q2 and 24.8% in the first half of th...
Elon Musk's Tesla and SpaceX are both pursuing leadership in AI but with very different approaches. Tesla focuses on AI-powered robotics and autonomous vehicles, investing heavily in chip production and Robotaxi expansion, though it currently faces n...
DHT Holdings saw a 45.4% sequential rise in VLCC spot market day rates in Q2, driving a 23.1% rally in its share price and strong dividend prospects with a forward yield of 24%. The company's low operating costs, young fleet, and reduced debt positio...
Procter & Gamble reported weak fiscal year 2026 results with only 1% organic sales and core earnings per share growth. The company forecasts modest 1–3% organic sales growth for fiscal year 2027 amid challenges from rising private label competition, ...
Bitcoin recently broke out and reached a key resistance level at $82,350 before pulling back. The price action has shifted into an ascending channel, suggesting potential for another attempt to surpass the critical macro high of $82,825. If bulls mai...
